RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/28507129http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/28507129http://www.w3.org/2000/01/rdf-schema#comment"Narcolepsy-cataplexy is a debilitating disorder of sleep/wakefulness caused by a loss of orexin-producing neurons in the lateroposterior hypothalamus. Genetic or pharmacologic orexin replacement ameliorates symptoms in mouse models of narcolepsy-cataplexy. We have recently discovered a potent, nonpeptide OX2R-selective agonist, YNT-185. This study validates the pharmacological activity of this compound in OX2R-transfected cells and in OX2R-expressing neurons in brain slice preparations. Intraperitoneal, and intracerebroventricular, administration of YNT-185 suppressed cataplexy-like episodes in orexin knockout and orexin neuron-ablated mice, but not in orexin receptor-deficient mice. Peripherally administered YNT-185 also promotes wakefulness without affecting body temperature in wild-type mice. Further, there was no immediate rebound sleep after YNT-185 administration in active phase in wild-type and orexin-deficient mice. No desensitization was observed after repeated administration of YNT-185 with respect to the suppression of cataplexy-like episodes. These results provide a proof-of-concept for a mechanistic therapy of narcolepsy-cataplexy by OX2R agonists."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.org/dc/terms/identifier"doi:10.1073/pnas.1700499114"xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Ishikawa Y."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Kanda T."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Sakurai T."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Ogawa Y."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Yanagisawa M."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Saitoh T."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Vogt K."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Nakajima R."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Uchida S."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Hosokawa N."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Nagase H."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Tominaga H."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Kawabe Y."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Irukayama-Tomobe Y."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/author"Ambai S."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/date"2017"xsd:gYear
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/name"Proc Natl Acad Sci U S A"xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/pages"5731-5736"xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/title"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models."xsd:string
http://purl.uniprot.org/citations/28507129http://purl.uniprot.org/core/volume"114"xsd:string
http://purl.uniprot.org/citations/28507129http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/28507129
http://purl.uniprot.org/citations/28507129http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/28507129